3 Growth Shares For Your Nisa: AstraZeneca plc, Diageo plc And Unilever plc

AstraZeneca plc (LON:AZN), Diageo plc (LON:DGE) and Unilever plc (LON:ULVR) look to be three great growth picks for your new ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At the beginning of this month the much touted New ISA, or Nisa, came into existence.

The Nisa is a revolution for savers. The new product has a limit of £15,000, a substantial increase from the £11,880 allowed in the previous Stocks & Shares ISA. What’s more, you will be able to move freely between shares and cash at any time using the full £15,000 to invest in the stock market, cash or a mix of both.

For those investors who want to add some spice to their Nisa, here are three companies that are set to see their profits surge over the next few years.

Best of both worldsastrazeneca

Recent takeover candidate, AstraZeneca (LSE: AZN) (NYSE: AZN.US) is not only a company with great growth potential, the company’s shares also currently support a 4% dividend yield.

As part of its attempt to rebuff Pfizer, Astra made the claim that the company had the potential to nearly double its annual sales during the next 10 years — from $26 billion today to $45 billion by 2023.

If the company pulls it off, shareholders will be richly rewarded. There is no reason to suggest that the company cannot hit these lofty targets.

Indeed, it is believed that Astra’s current pipeline of oncology treatments is one of the best in the world. The company’s set of AZD9291 cancer treatments is expected to rack up sales of $3 billion, as its flexible nature means that the drug can be combined with other treatments to make several completely different products.

However, at present Astra’s sales are contracting, although current forecasts predict that they will start expanding again during 2016 and 2017. With a dividend yield of 4%, investors will be paid to wait.

Rapid expansion

DiageoDiageo’s (LSE: DGE) (NYSE: DEO.US) growth over the past decade has been nothing short of impressive. Nevertheless, it would appear that the company is just getting started.

Diageo has built itself into the largest alcoholic beverage brand in the world. The company’s drinks cabinet now contains some of the world’s best-known drinks brands including GuinnessSmirnoff vodka and Johnnie Walker whiskey.

Recently the company acquired around 50% of United Spirits, India’s largest spirit company. India’s whiskey consumption doubled during the period 2005 to 2010 and for Diageo, this market has remained largely out of reach.

Strict import laws and tariffs have prevent from Diego from entering the world’s largest whiskey market but control of United Spirits should change that.

Over the long term, Diageo is sure to profit from its Indian expansion.

Emerging marketsUnilever

My final Nisa growth pick is another play on India. Consumer goods giant, Unilever (LSE: ULVR) recently increased its stake in Hindustan Unilever Limited; Unilever’s Indian subsidiary. India is one of the world’s largest consumer markets, so Unilever’s presence within the region is exciting.

Further, Unilever is refocusing its global brand portfolio, selling off non-core, low-margin and low-growth food brands, diverting funds towards the company’s line of home care products. The home care side of the business is actually growing much faster than the food side.

Unilever is a solid pick for income seekers as well. The company currently supports a dividend yield of 3.4%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert does not own any share mentioned within this article. The Motley Fool owns shares in Unilever. 

More on Investing Articles

Investing Articles

10%+ dividend growth! 2 FTSE 250 shares tipped to turbocharge dividends

These FTSE 250 income shares look in great shape to grow their dividends by double-digit percentages, says our writer Royston…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Would it be madness to buy this FTSE stock smashed by Donald Trump’s team picks?

Ben McPoland takes a look at one FTSE share inside his portfolio that has been battered lately due to a…

Read more »

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »